# LCP-Tacro vs. Azathioprine for the Treatment of Autoimmune Hepatitis

> **NCT00608894** · PHASE2 · TERMINATED · sponsor: **Veloxis Pharmaceuticals** · enrollment: 13 (actual)

## Conditions studied

- Autoimmune Hepatitis

## Interventions

- **DRUG:** LCP-Tacro (tacrolimus)
- **DRUG:** Azathioprine

## Key facts

- **NCT ID:** NCT00608894
- **Lead sponsor:** Veloxis Pharmaceuticals
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2007-12
- **Primary completion:** 2009-04
- **Final completion:** 2009-07
- **Target enrollment:** 13 (ACTUAL)
- **Why stopped:** Study was discontinued due to slow enrollment
- **Last updated:** 2020-03-17


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00608894

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00608894, "LCP-Tacro vs. Azathioprine for the Treatment of Autoimmune Hepatitis". Retrieved via AI Analytics 2026-09-14 from https://api.ai-analytics.org/clinical/NCT00608894. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*